Tham khảo Hydroxyprogesterone caproate

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 Deeks ED (tháng 10 năm 2011). “17 α-Hydroxyprogesterone caproate (Makena™): in the prevention of preterm birth”. Paediatric Drugs 13 (5): 337–45. PMID 21888448. doi:10.2165/11208140-000000000-00000.
1 2 3 4 Krop J, Kramer WG (tháng 12 năm 2017). “Comparative Bioavailability of Hydroxyprogesterone Caproate Administered via Intramuscular Injection or Subcutaneous Autoinjector in Healthy Postmenopausal Women: A Randomized, Parallel Group, Open-label Study”. Clinical Therapeutics 39 (12): 2345–2354. PMID 29191450. doi:10.1016/j.clinthera.2017.10.020.
1 2 3 4 5 6 7 8 9 10 11 12 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021945s012lbl.pdf
1 2 3 4 5 Shaik IH, Bastian JR, Zhao Y, Caritis SN, Venkataramanan R (2015). “Route of administration and formulation dependent pharmacokinetics of 17-hydroxyprogesterone caproate in rats”. Xenobiotica; the Fate of Foreign Compounds in Biological Systems 46 (2): 169–74. PMC 4809632. PMID 26153441. doi:10.3109/00498254.2015.1057547.
1 2 Mickelson KE, Forsthoefel J, Westphal U (tháng 10 năm 1981). “Steroid-protein interactions. Human corticosteroid binding globulin: some physicochemical properties and binding specificity”. Biochemistry 20 (21): 6211–8. PMID 7306509. doi:10.1021/bi00524a047.
1 2 Dunn JF, Nisula BC, Rodbard D (tháng 7 năm 1981). “Transport of steroid hormones: binding of 21 endogenous steroids to both testosterone-binding globulin and corticosteroid-binding globulin in human plasma”. The Journal of Clinical Endocrinology and Metabolism 53 (1): 58–68. PMID 7195404. doi:10.1210/jcem-53-1-58.
↑ Onsrud M, Paus E, Haug E, Kjørstad K (1985). “Intramuscular administration of hydroxyprogesterone caproate in patients with endometrial carcinoma. Pharmacokinetics and effects on adrenal function”. Acta Obstetricia et Gynecologica Scandinavica 64 (6): 519–23. PMID 2932883. doi:10.3109/00016348509156732.
1 2 3 4 5 Hines M, Lyseng-Williamson KA, Deeks ED (tháng 3 năm 2013). “17 α-hydroxyprogesterone caproate (Makena®): a guide to its use in the prevention of preterm birth”. Clinical Drug Investigation 33 (3): 223–7. PMID 23413110. doi:10.1007/s40261-013-0060-6.
1 2 3 4 5 6 7 8 9 10 11 12 Feghali M, Venkataramanan R, Caritis S (tháng 12 năm 2014). “Prevention of preterm delivery with 17-hydroxyprogesterone caproate: pharmacologic considerations”. Seminars in Perinatology 38 (8): 516–22. PMC 4253874. PMID 25256193. doi:10.1053/j.semperi.2014.08.013.
↑ Manuck TA (tháng 12 năm 2017). “17-alpha hydroxyprogesterone caproate for preterm birth prevention: Where have we been, how did we get here, and where are we going?”. Seminars in Perinatology 41 (8): 461–467. PMID 28947068. doi:10.1053/j.semperi.2017.08.004.
1 2 Newton JR, D'arcangues C, Hall PE (1994). “A review of "once-a-month" combined injectable contraceptives”. Journal of Obstetrics and Gynaecology. 4 Suppl 1: S1–34. PMID 12290848. doi:10.3109/01443619409027641.
1 2 3 4 Romero R, Stanczyk FZ (tháng 6 năm 2013). “Progesterone is not the same as 17α-hydroxyprogesterone caproate: implications for obstetrical practice”. American Journal of Obstetrics and Gynecology 208 (6): 421–6. PMC 4120746. PMID 23643669. doi:10.1016/j.ajog.2013.04.027.
1 2 Horsky J, Presl J (6 tháng 12 năm 2012). Ovarian Function and its Disorders: Diagnosis and Therapy. Springer Science & Business Media. tr. 95–. ISBN 978-94-009-8195-9.
1 2 3 Dorfman RI (5 tháng 12 năm 2016). Steroidal Activity in Experimental Animals and Man. Elsevier Science. tr. 398–. ISBN 978-1-4832-7299-3. Intramuscular administration of 17α-hydroxyprogesterone caproate produced signs and symptoms of adrenal insufficiency in Addisonians maintained on cortisol and 9α-fluorocortisol (Melby, 1961) and thereby showed properties similar to progesterone and 17α-hydroxyprogesterone. However, further tests will be required to eludicate its pharmacodynamics properties. Contrastingly, there was no evidence for salt dissipation with the test of a smaller dose of the steroid to normal subjects (Landau et al., 1958).
1 2 3 Sammour MB, El-Kabarity H, Khalifa AS (1975). “Progesterone therapy in pre-eclamptic toxaemia”. Acta Obstetricia et Gynecologica Scandinavica 54 (3): 195–202. PMID 1163210. doi:10.3109/00016347509157760. Melby (14) found that when progesterone was administered to patients suffering from the syndrome of idiopathic oedema, they experienced a diuresis, with a high excretion of sodium and water within 24 hours after a single injection of 500 mg of 17-α-hydroxyprogesterone caproate.
1 2 3 4 Geller J, Bora R, Roberts T, Newman H, Lin A, Silva R (tháng 7 năm 1965). “Treatment of benign prostatic hypertrophy with hydroxyprogesterone caproate: effect on clinical symptoms, morphology, and endocrine function”. JAMA 193 (2): 121–8. PMID 14304354. doi:10.1001/jama.1965.03090020035009.
1 2 3 4 5 6 Meis PJ (tháng 5 năm 2005). “17 hydroxyprogesterone for the prevention of preterm delivery”. Obstetrics and Gynecology 105 (5 Pt 1): 1128–35. PMID 15863556. doi:10.1097/01.AOG.0000160432.95395.8f.
1 2 3 4 5 6 7 Byrns MC (tháng 1 năm 2014). “Regulation of progesterone signaling during pregnancy: implications for the use of progestins for the prevention of preterm birth”. The Journal of Steroid Biochemistry and Molecular Biology 139: 173–81. PMID 23410596. doi:10.1016/j.jsbmb.2013.01.015.
1 2 International Agency for Research on Cancer (1979). Sex Hormones (II). International Agency for Research on Cancer. tr. 401. ISBN 978-92-832-1221-8. 17α-Hydroxyprogesterone caproate was first marketed commercially in Japan in 1954-1955.
1 2 3 4 5 6 7 8 9 10 Index Nominum 2000: International Drug Directory. Taylor & Francis. Tháng 1 năm 2000. tr. 532–. ISBN 978-3-88763-075-1.
1 2 Kim S. “The Orphan Drug Act: How the FDA Unlawfully Usurped Market Exclusivity”. Northwestern Journal of Technology and Intellectual Property (Heinonline) 11: [v&#93.
1 2 3 4 5 6 7 8 9 Armstrong J (tháng 5 năm 2011). “Unintended consequences--the cost of preventing preterm births after FDA approval of a branded version of 17OHP”. The New England Journal of Medicine 364 (18): 1689–91. PMID 21410391. doi:10.1056/NEJMp1102796.
1 2 “Macleans.ca - Canada's national current affairs and news magazine since 1905”. Bản gốc lưu trữ ngày 14 tháng 12 năm 2011. Truy cập ngày 30 tháng 3 năm 2011.
1 2 Research, Center for Drug Evaluation and (1 tháng 4 năm 2019). “Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A of the Federal Food, Drug, and Cosmetic Act Guidance for Industry”. U.S. Food and Drug Administration (bằng tiếng Anh). Truy cập ngày 14 tháng 6 năm 2019.
1 2 “FDA to Restrict Compounders from Making Copies of Commercially Available Drugs”. RAPS.com. 7 tháng 7 năm 2016. Truy cập ngày 14 tháng 6 năm 2019.
↑ SMFM Clinical Guideline: Progesterone and preterm birth prevention: translating clinical trials data into clinical practice, AJOG May 2012
1 2 Meis PJ, Klebanoff M, Thom E, Dombrowski MP, Sibai B, Moawad AH và đồng nghiệp (tháng 6 năm 2003). “Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate”. The New England Journal of Medicine 348 (24): 2379–85. PMID 12802023. doi:10.1056/NEJMoa035140.
1 2 3 4 5 6 “Hydroxyprogesterone”.
1 2 3 Benign Prostatic Hypertrophy. Springer Science & Business Media. 6 tháng 12 năm 2012. tr. 266–. ISBN 978-1-4612-5476-8.
1 2 Ablin RJ, Mason MD (5 tháng 9 năm 2007). Metastasis of Prostate Cancer. Springer Science & Business Media. tr. 286–. ISBN 978-1-4020-5847-9.
↑ Smith PH (29 tháng 6 năm 2013). Cancer of the Prostate and Kidney. Springer Science & Business Media. tr. 309,339. ISBN 978-1-4684-4349-3.
1 2 Hafez ES, Spring-Mills E (6 tháng 12 năm 2012). Prostatic Carcinoma: Biology and Diagnosis. Springer Science & Business Media. tr. 128–. ISBN 978-94-009-8887-3.
1 2 3 Castro JE (9 tháng 3 năm 2013). The Treatment of Prostatic Hypertrophy and Neoplasia. Springer Science & Business Media. tr. 39,132. ISBN 978-94-015-7190-6. Geller has also demonstrated significant decreases in plasma or urine testosterone glucuronide levels following the administration of three other anti-androgens. These include Delalutin [hydroxyprogesterone caproate], chlormadinone acetate, and PH-218. It would appear that decreased androgen production is a property shared by all anti-androgens to date.
↑ Aronson JK (21 tháng 2 năm 2009). Meyler's Side Effects of Endocrine and Metabolic Drugs. Elsevier. tr. 289–. ISBN 978-0-08-093292-7.
↑ Israel GE, Tarver DE, Shaffer JD (1 tháng 3 năm 2001). Transgender Care: Recommended Guidelines, Practical Information, and Personal Accounts. Temple University Press. tr. 58–. ISBN 978-1-56639-852-7.
↑ Ekins R, King D (23 tháng 10 năm 2006). The Transgender Phenomenon. SAGE Publications. tr. 48–. ISBN 978-1-84787-726-0.
↑ Adler RK, Hirsch S, Mordaunt M (1 tháng 5 năm 2012). Voice and Communication Therapy for The Transgender/Transsexual Client: A Comprehensive Clinical Guide. Plural Publishing. tr. 486–. ISBN 978-1-59756-631-5.
↑ Masumori N (tháng 5 năm 2012). “Status of sex reassignment surgery for gender identity disorder in Japan”. International Journal of Urology 19 (5): 402–14. PMID 22372595. doi:10.1111/j.1442-2042.2012.02975.x.
↑ Chekir C, Emi Y, Arai F, Kikuchi Y, Sasaki A, Matsuda M, Shimizu K, Tabuchi K, Kamada Y, Hiramatsu Y, Nakatsuka M (tháng 6 năm 2012). “Altered arterial stiffness in male-to-female transsexuals undergoing hormonal treatment”. The Journal of Obstetrics and Gynaecology Research 38 (6): 932–40. PMID 22487218. doi:10.1111/j.1447-0756.2011.01815.x.
1 2 Baker KC (tháng 11 năm 1958). “Treatment of persistent acne in women with 17 alpha hydroxyprogesterone caproate (delalutin); a preliminary report”. The Journal of Investigative Dermatology 31 (5): 247–50. PMID 13598928. doi:10.1038/jid.1958.114.
↑ Antibiotic Medicine and Clinical Therapy. 1959. tr. 249.
1 2 Becker KL (2001). Principles and Practice of Endocrinology and Metabolism. Lippincott Williams & Wilkins. tr. 757–759,2168. ISBN 978-0-7817-1750-2.
↑ Nema S, Ludwig JD (19 tháng 4 năm 2016). Pharmaceutical Dosage Forms - Parenteral Medications, Third Edition: Volume 1: Formulation and Packaging. CRC Press. tr. 161–. ISBN 978-1-4200-8644-7.
1 2 Muller NF, Dessing RP (19 tháng 6 năm 1998). European Drug Index: European Drug Registrations . CRC Press. tr. 561–. ISBN 978-3-7692-2114-5.
1 2 Garza-Flores J (tháng 4 năm 1994). “Pharmacokinetics of once-a-month injectable contraceptives”. Contraception 49 (4): 347–59. PMID 8013219. doi:10.1016/0010-7824(94)90032-9.
1 2 3 4 5 Sang GW (tháng 4 năm 1994). “Pharmacodynamic effects of once-a-month combined injectable contraceptives”. Contraception 49 (4): 361–85. PMID 8013220. doi:10.1016/0010-7824(94)90033-7.
1 2 Bagade O, Pawar V, Patel R, Patel B, Awasarkar V, Diwate S (2014). “Increasing use of long-acting reversible contraception: safe, reliable, and cost-effective birth control” (PDF). World J Pharm Pharm Sci 3 (10): 364–392. ISSN 2278-4357.
1 2 3 Leidenberger FA (17 tháng 4 năm 2013). Klinische Endokrinologie für Frauenärzte. Springer-Verlag. tr. 533–. ISBN 978-3-662-08110-5.
1 2 3 4 5 Knörr K, Beller FK, Lauritzen C (17 tháng 4 năm 2013). Lehrbuch der Gynäkologie. Springer-Verlag. tr. 214,255. ISBN 978-3-662-00942-0.
1 2 3 Kahr H (8 tháng 3 năm 2013). Konservative Therapie der Frauenkrankheiten: Anzeigen, Grenzen und Methoden Einschliesslich der Rezeptur. Springer-Verlag. tr. 22–. ISBN 978-3-7091-5694-0.
1 2 3 Kern W, Auterhoff H, Neuwald F, Schmid W (9 tháng 3 năm 2013). Hagers Handbuch der Pharmazeutischen Praxis: Für Apotheker, Arzneimittelhersteller, Drogisten, Ärzte und Medizinalbeamte. Springer-Verlag. tr. 1163–. ISBN 978-3-642-49759-9.
1 2 3 4 5 6 7 8 Ufer, Joachim (1968). “Die therapeutische Anwendung der Gestagene beim Menschen” [Therapeutic Use of Progestogens in Humans]. Die Gestagene [Progestogens]. Springer-Verlag. tr. 1026–1124. ISBN 978-3-642-99941-3. doi:10.1007/978-3-642-99941-3_7. Depotinjektionen [...] 2. Einmalige Injektion von 125mg oder 250mg 17α-Hydroxyprogesteroncapronat als Depotgestagen und 10 mg Oestradiolbenzoat in öliger Lösung (Primosiston) [47, 81, 110, 563, 523, 571, 718, 721, 732, 733, 864, 872, 933, 973, 400].
↑ https://www.drugs.com/international/ep-hormone.html
↑ Noguchi M, Tajiri K, Taniya T, Kumaki T, Ashikari A, Miyazaki I (1990). “Influence of hormones on proliferation of ER-positive cells and ER-negative cells of human breast cancer (MCF-7)”. Oncology 47 (1): 19–24. PMID 2137212. doi:10.1159/000226779. After the transplantation, each mouse received an intramuscular injection of 0.1 ml EP Hormone Depot consisting of 1 mg/ml 17-β-estradiol dipropionate and 50 mg/ml hydroxyprogesterone caproate every week.
1 2 Hall NR (tháng 6 năm 2011). “What agent should be used to prevent recurrent preterm birth: 17-P or natural progesterone?”. Obstetrics and Gynecology Clinics of North America 38 (2): 235–46, ix–x. PMID 21575799. doi:10.1016/j.ogc.2011.02.014.
1 2 Varga A, Henriksen E. Clinical and Histopathologic Evaluation of the Effect of 17-alpha-Hydroxyprogesterone-17-n-caproate on Endometrial Carcinoma. Obstetrics & Gynecology. December 1961. Volume 18. Issue 6. pp. 658-672.
1 2 Kuhl H (tháng 8 năm 2005). “Pharmacology of estrogens and progestogens: influence of different routes of administration” (PDF). Climacteric. 8 Suppl 1: 3–63. PMID 16112947. doi:10.1080/13697130500148875.
1 2 Knörr K, Knörr-Gärtner H, Beller FK, Lauritzen C (8 tháng 3 năm 2013). Geburtshilfe und Gynäkologie: Physiologie und Pathologie der Reproduktion. Springer-Verlag. tr. 583–. ISBN 978-3-642-95583-9.
↑ Lauritzen C (tháng 9 năm 1990). “Clinical use of oestrogens and progestogens”. Maturitas 12 (3): 199–214. PMID 2215269. doi:10.1016/0378-5122(90)90004-P.
1 2 Toppozada MK (tháng 4 năm 1994). “Existing once-a-month combined injectable contraceptives”. Contraception 49 (4): 293–301. PMID 8013216. doi:10.1016/0010-7824(94)90029-9.
1 2 Siegel I (tháng 6 năm 1963). “Conception control by long-acting progestogens: preliminary report”. Obstetrics and Gynecology 21: 666–8. PMID 13992789. doi:10.1097/00006250-196306000-00003 (không tích cực 2019-05-19).
↑ Kistner RW (tháng 12 năm 1960). “The use of progestational agents in obstetrics and gynecology”. Clinical Obstetrics and Gynecology 3 (4): 1047–67. PMID 13756432. doi:10.1097/00003081-196003040-00019. 50 mg of [medroxyprogesterone acetate], intramuscularly, is equivalent to 250 mg [hydroxyprogesterone caproate]
↑ “Depo_Provera” (PDF). FDA. 2016. Truy cập ngày 31 tháng 3 năm 2018.
1 2 3 4 5 6 7 8 Attardi BJ, Zeleznik A, Simhan H, Chiao JP, Mattison DR, Caritis SN (tháng 12 năm 2007). “Comparison of progesterone and glucocorticoid receptor binding and stimulation of gene expression by progesterone, 17-alpha hydroxyprogesterone caproate, and related progestins”. American Journal of Obstetrics and Gynecology 197 (6): 599.e1–7. PMC 2278032. PMID 18060946. doi:10.1016/j.ajog.2007.05.024.
↑ Yang D, Zhu RL (tháng 4 năm 1994). “[Changes in reproductive hormones levels in the treatment of endometrial precancerous lesion with hydroxyprogesterone caproate]”. Zhonghua Fu Chan Ke Za Zhi (bằng tiếng Trung Quốc) 29 (4): 205–6, 251. PMID 8082440. In this paper, 14 cases of precancerous lesion of endometrium were treated with hydroxyprogesterone caproate and a series of hormone determination was analysed before and after treatment. Results showed that LH and LH/FSH were dramatically decreased. (LH P < 0.05, LH/FSH P < 0.01). Bảo trì CS1: Ngôn ngữ không rõ (link)
↑ Benign Prostatic Hypertrophy. Springer Science & Business Media. 6 tháng 12 năm 2012. tr. 266–. ISBN 978-1-4612-5476-8. Since the initial report by Geller and associates28 on the use of hydroxyprogesterone caproate in the treatment of BPH, a variety of progestins have been studied in the medical management of this disease: hydroxyprogesterone caproate, chlormadinone acetate,27 and medrogestone (6-methyl-6-dehydro-17-methylprogesterone).50 These drugs should have a beneficial effect in BPH as they inhibit testicular function by suppressing serum LH and have no intrinsic estrogenic or androgenic activity.
↑ Meiraz D, Margolin Y, Lev-Ran A, Lazebnik J (tháng 2 năm 1977). “Treatment of benign prostatic hyperplasia with hydroxyprogesterone-caproate: placebo-controlled study”. Urology 9 (2): 144–8. PMID 65818. doi:10.1016/0090-4295(77)90184-4.
↑ Karlstedt K (tháng 4 năm 1971). “Progesterone treatment for local recurrence and metastases in carcinoma corporis uteri”. Acta Radiologica 10 (2): 187–92. PMID 5556820. doi:10.3109/02841867109129755. The preparations used were Proluton Depot (17a-hydroxy-progesterone caproate) and in 3 patients SH 5132 (17a-hydroxy-19-norprogesterone caproate); 100 mg of the latter corresponds to 1000 mg of Proluton Depot.
1 2 Moe N (1972). “Short-term progestogen treatment of endometrial carcinoma. Histological, histochemical and hormonal studies”. Acta Obstetricia et Gynecologica Scandinavica 51 (1): 55–62. PMID 4261828. doi:10.3109/00016347209154968.
1 2 3 Sander S, Nissen-Meyer R, Aakvaag A (1978). “On gestagen treatment of advanced prostatic carcinoma”. Scandinavian Journal of Urology and Nephrology 12 (2): 119–21. PMID 694436. doi:10.3109/00365597809179977.
1 2 Kjeld JM, Puah CM, Kaufman B, Loizou S, Vlotides J, Gwee HM, Kahn F, Sood R, Joplin GF (tháng 11 năm 1979). “Effects of norgestrel and ethinyloestradiol ingestion on serum levels of sex hormones and gonadotrophins in men”. Clinical Endocrinology 11 (5): 497–504. PMID 519881. doi:10.1111/j.1365-2265.1979.tb03102.x. Another synthetic gestogen, 17-hydroxy-19-norprogesterone caproate (Depostat-Schering), 400 mg by i.m. weekly injections suppressed T levels to 25% of pretreatment values (Sander er al., 1978).
↑ Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA (25 tháng 8 năm 2011). Campbell-Walsh Urology: Expert Consult Premium Edition: Enhanced Online Features and Print, 4-Volume Set. Elsevier Health Sciences. tr. 2938–. ISBN 978-1-4160-6911-9.
↑ Knuth UA, Hano R, Nieschlag E (tháng 11 năm 1984). “Effect of flutamide or cyproterone acetate on pituitary and testicular hormones in normal men”. The Journal of Clinical Endocrinology and Metabolism 59 (5): 963–9. PMID 6237116. doi:10.1210/jcem-59-5-963.
↑ Jacobi GH, Altwein JE, Kurth KH, Basting R, Hohenfellner R (tháng 6 năm 1980). “Treatment of advanced prostatic cancer with parenteral cyproterone acetate: a phase III randomised trial”. British Journal of Urology 52 (3): 208–15. PMID 7000222. doi:10.1111/j.1464-410x.1980.tb02961.x.
↑ Sherman AI, Woolf RB (tháng 2 năm 1959). “An endocrine basis for endometrial carcinoma”. American Journal of Obstetrics and Gynecology 77 (2): 233–42. PMID 13617315. doi:10.1016/0002-9378(59)90223-6.
↑ Geer EB (1 tháng 12 năm 2016). The Hypothalamic-Pituitary-Adrenal Axis in Health and Disease: Cushing's Syndrome and Beyond. Springer. tr. 28–. ISBN 978-3-319-45950-9.
↑ Aschenbrenner DS, Venable SJ (2009). Drug Therapy in Nursing. Lippincott Williams & Wilkins. tr. 674–. ISBN 978-0-7817-6587-9.
↑ Gerber AN, Masuno K, Diamond MI (tháng 3 năm 2009). “Discovery of selective glucocorticoid receptor modulators by multiplexed reporter screening”. Proceedings of the National Academy of Sciences of the United States of America 106 (12): 4929–34. Bibcode:2009PNAS..106.4929G. PMC 2660744. PMID 19255438. doi:10.1073/pnas.0812308106.
1 2 Bardin CW, Brown T, Isomaa VV, Jänne OA (1983). “Progestins can mimic, inhibit and potentiate the actions of androgens”. Pharmacology & Therapeutics 23 (3): 443–59. PMID 6371845. doi:10.1016/0163-7258(83)90023-2.
1 2 3 Caritis SN, Sharma S, Venkataramanan R, Hankins GD, Miodovnik M, Hebert MF, Umans JG, Benedetti T, Mattison D, Zajicek A, Fischer D, Jackson A (tháng 11 năm 2012). “Pharmacology and placental transport of 17-hydroxyprogesterone caproate in singleton gestation”. American Journal of Obstetrics and Gynecology 207 (5): 398.e1–8. PMC 3586341. PMID 22967833. doi:10.1016/j.ajog.2012.08.015.
1 2 Caritis SN, Sharma S, Venkataramanan R, Rouse DJ, Peaceman AM, Sciscione A, Spong CY, Varner MW, Malone FD, Iams JD, Mercer BM, Thorp JM, Sorokin Y, Carpenter M, Lo J, Ramin S, Harper M (tháng 7 năm 2011). “Pharmacokinetics of 17-hydroxyprogesterone caproate in multifetal gestation”. American Journal of Obstetrics and Gynecology 205 (1): 40.e1–8. PMC 3165062. PMID 21620357. doi:10.1016/j.ajog.2011.03.028.
↑ Ferin J (tháng 9 năm 1972). “Orally Active Progestational Compounds. Human Studies: Effects on the Utero-Vaginal Tract”. Trong M. Tausk. Pharmacology of the Endocrine System and Related Drugs: Progesterone, Progestational Drugs and Antifertility Agents II. Pergamon Press. tr. 245–273. ISBN 978-0080168128. OCLC 278011135.
1 2 3 “Hydroxyprogesterone caproate oral - Lipocine - AdisInsight”.
1 2 DelConte A, Chidambaram N, Nachaegari S, Patel M, Venkateshwaran S (tháng 1 năm 2015). “770: Pharmacokinetics and tolerability of oral 17-hydroxyprogesterone caproate (HPC) relative to intramuscular (IM) HPC.”. American Journal of Obstetrics & Gynecology 212 (1): S374. doi:10.1016/j.ajog.2014.10.976.
↑ Boggess KA, Baker JB, Murtha AP, Peaceman AM, Shah DM, Siegfried SL, Birch R (tháng 4 năm 2018). “Pharmacokinetics of Hydroxyprogesterone Caproate and its Primary Metabolites during Pregnancy”. AJP Reports 8 (2): e106–e112. PMC 5951785. PMID 29765789. doi:10.1055/s-0038-1639331.
1 2 https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021945s000lbl.pdf
1 2 Ferin J (tháng 9 năm 1972). “Effects, Duration of Action and Metabolism in Man”. Trong Tausk M. Pharmacology of the Endocrine System and Related Drugs: Progesterone, Progestational Drugs and Antifertility Agents II. Pergamon Press. tr. 13–24. ISBN 978-0080168128. OCLC 278011135.
↑ Santhosh, C. R. (2006). Pharmacokinetics of 17α-Hydroxy Progesterone Caproate in Cattle, Buffalo, Sheep and Goat (Doctoral dissertation, Karnataka Veterinary, Animal and Fisheries Sciences University, Bidar). http://krishikosh.egranth.ac.in/handle/1/68575
1 2 3 4 5 6 7 Elks J (14 tháng 11 năm 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. tr. 664–. ISBN 978-1-4757-2085-3.
↑ Engel J, Kleemann A, Kutscher B, Reichert D (14 tháng 5 năm 2014). Pharmaceutical Substances, 5th Edition, 2009: Syntheses, Patents and Applications of the most relevant APIs. Thieme. tr. 677–679. ISBN 978-3-13-179275-4.
↑ William Andrew Publishing (22 tháng 10 năm 2013). Pharmaceutical Manufacturing Encyclopedia. Elsevier. tr. 1865–1866. ISBN 978-0-8155-1856-3.
↑ Junkmann, Karl; Langecker, Hedwig; Damrosch, Leonore (1968). “Chemie der Gestagene” [Chemistry of Progestogens]. Die Gestagene [Progestogens]. Springer-Verlag. tr. 1–44. ISBN 978-3-642-99941-3. doi:10.1007/978-3-642-99941-3_1. 3. Hydroxyprogesteron-caproat. C27H4004, Mol.-Gew.: 428,62; chemische Bezeichnung Δ4-Pregnen-17α-ol-3,20-dion-17α-capronat, Trivialnamen: Hydroxyprogesteroncapronat, 17α-Hydroxyprogesteron-17α-capronat. Synthese: [88]. Darstellung: [88]. Eigenschaften: weißes kristallines Pulver (aus Isopropyläther) oder Methanol, F.: 119-122⁰, [α]D: +60⁰ (Chlf.) UV-Absorption: λmax.: 240 mμ, ε = 17000. Dipolmoment: [μ = 2,21 (Benzol). Leicht löslich in Äthanol, Äther, Essigester, Benzol, Chloroform, löslich in: Petroläther, unlöslich in Wasser. Bei 20⁰ lösen 100 ml Sesamöl ca. 4,0 g, Ricinusöl ca. 2,5 g, Ricinusöl: Benzylbenzoat (4: 6) ca. 26,5 g, Benzylbenzoat ca. 36,0 g. [...] Abb. 3. IR-Spektrum [126] und Formel des Hydroxyprogesteron-caproat.
↑ Junkmann, Karl (1954). “Über protrahiert wirksame Gestagene”. Naunyn-Schmiedebergs Archiv für Experimentelle Pathologie und Pharmakologie 223 (3). doi:10.1007/BF00246995.
↑ Wied GL, Davis ME (tháng 7 năm 1958). “Comparative activity of progestational agents on the human endometrium and vaginal epithelium of surgical castrates”. Annals of the New York Academy of Sciences 71 (5): 599–616. Bibcode:1958NYASA..71..599W. PMID 13583817. doi:10.1111/j.1749-6632.1958.tb46791.x. In the group of new parenteral progestational agents, three substances developed by Karl Junkmann1,2 are the most outstanding and interesting: 17a-hydroxyprogesterone caproate and 17a-hydroxyprogesterone acetate, introduced in 1953, and the most potent of all new parenteral progestational agents, 17-ethynyl-19-nortestosterone enanthate, introduced in 1956.
↑ ACRH. U.S. Dept. of Energy. 1960. tr. 71. [The] minimal activity [of 17(a)-hydroxyprogesterone] is magnified to an unexpected degree by the esterification of this steroid with caproic acid to produce 17(a)-hydroxyprogesterone-17-n-caproate, first reported by Karl Junkmann in 1954.6,7
↑ Dorfman RI (1966). Methods in Hormone Research. Academic Press. tr. 86. Junkmann (1954) reported that the acetate, butyrate, and caproate forms had both increased and prolonged activity, [...]
↑ Applezweig N (1962). Steroid Drugs. Blakiston Division, McGraw-Hill. tr. 101–102. Junkmann of Schering, AG., however, was able to show that long chain esters of 17a-hydroxyprogesterones such as the 17a-caproate produced powerful long-acting progestational effect. This compound is marketed in the United States as Delalutin by Squibb, and has been heavily used for the treatment of habitual abortion.
↑ New and Nonofficial Drugs. Lippincott. 1958. tr. 662. Supplied by.—E. R. Squibb & Sons (Delalutin). Year of introduction: 1956.
↑ Tausk M (1975). Pharmacology of hormones. Thieme. tr. 105. ISBN 978-3-13-518901-7. Progesterone itself is now almost never used for the management of any imminent threat to pregnancy. For oral therapy, it is in any event unsuitable and for injections, it has now been replaced by the long-acting esters of 17α-hydroxyprogesterone. The caproate (Proluton, Delalutin), a long-acting ester, is available in [...] Progesterone is rarely used therapeutically. It has largely been superseded by a long-acting ester of 17α-hydroxyprogesterone, for parenteral therapy.
↑ FDA press release regarding Makena approval
↑ O'Brien JM (tháng 9 năm 2013). “Medication safety is still an issue in obstetrics 50 years after the Kefauver-Harris amendments: the case of progestogens”. Ultrasound in Obstetrics & Gynecology 42 (3): 247–53. PMID 23495199. doi:10.1002/uog.12456.
1 2 3 Sweetman, Sean C. biên tập (2009). “Sex hormones and their modulators”. Martindale: The Complete Drug Reference (ấn bản 36). London: Pharmaceutical Press. tr. 2110–2111. ISBN 978-0-85369-840-1.
↑ “Price of preterm birth medicine cut”. Boston.com. Associated Press. 2 tháng 4 năm 2011. Truy cập ngày 2 tháng 4 năm 2011.
↑ Goldsmith A, Toppozada M (1983). “Long-acting contraception”. Symposium on Long-Acting Contraception (Alexandria, Egypt). Chicago, Illinois: Northwestern University, Program for Applied Research on Fertility Regulation. tr. 94–95.
↑ Toppozada M (tháng 6 năm 1977). “The clinical use of monthly injectable contraceptive preparations”. Obstetrical & Gynecological Survey 32 (6): 335–47. PMID 865726. doi:10.1097/00006254-197706000-00001.
↑ Dao, Thomas L. (1975). “Pharmacology and Clinical Utility of Hormones in Hormone Related Neoplasms”. Trong Alan C. Sartorelli; David G. Johns. Antineoplastic and Immunosuppressive Agents. tr. 170–192. ISBN 978-3-642-65806-8. doi:10.1007/978-3-642-65806-8_11.
↑ Crowley, Lawrence G.; Macdonald, Ian (1962). “Clinical trial of Delalutin in the treatment of advanced mammary carcinoma in postmenopausal women”. Cancer 15 (6): 1218–1220. ISSN 0008-543X. PMID 14024037. doi:10.1002/1097-0142(196211/12)15:6<1218::AID-CNCR2820150619>3.0.CO;2-Y.
↑ Geller J, Volk H, Lewin M (tháng 10 năm 1961). “Objective remission of metastatic breast carcinoma in a male who received 17-alpha hydroxy progesterone caproate (Delalutin)”. Cancer Chemotherapy Reports 14: 77–81. ISSN 0069-0112. PMID 13897631.
↑ Crowley, Lawrence G.; Macdonald, Ian (1965). “Delalutin and estrogens for the treatment of advanced mammary carcinoma in the postmenopausal woman”. Cancer 18 (4): 436–446. ISSN 0008-543X. PMID 14278040. doi:10.1002/1097-0142(196504)18:4<436::AID-CNCR2820180407>3.0.CO;2-D.
↑ Crowley, L.G.; MacDonald, J. (1966). “Delalutin und Östrogene als Behandlung des vorgeschrittenen Mammakarzinoms bei Frauen nach der Menopause” [Delalutin and estrogens as a treatment for advanced breast cancer in postmenopausal women]. Gynäkologisch-geburtshilfliche Rundschau 3 (4): 271–272. ISSN 1018-8843. doi:10.1159/000266855.
↑ Firusian N, Schietzel M (tháng 9 năm 1976). “Zur additiven Therapie des metastasierenden Mamma-Karzinoms unter Berücksichtigung des Postmenopausalaltes (Ergebnisse einer randomisierten Studie)” [Additive treatment of metastasizing breast cancer with special reference to postmenopausal age (results of a randomized study)]. Strahlentherapie (bằng tiếng Đức) 152 (3): 235–47. ISSN 0039-2073. PMID 968923. Bảo trì CS1: Ngôn ngữ không rõ (link)